Foth S, Meller S, Kenward H, Elliott J, Pelligand L, Volk H
BMC Vet Res. 2021; 17(1):222.
PMID: 34154584
PMC: 8218477.
DOI: 10.1186/s12917-021-02931-9.
Barnes N, Ahern G, Becamel C, Bockaert J, Camilleri M, Chaumont-Dubel S
Pharmacol Rev. 2020; 73(1):310-520.
PMID: 33370241
PMC: 7770494.
DOI: 10.1124/pr.118.015552.
Koyama Y, Kondo M, Shimada S
Sci Rep. 2017; 7:42884.
PMID: 28276429
PMC: 5343592.
DOI: 10.1038/srep42884.
Guimaraes D, Andrews P, Rudd J, Braga V, Nalivaiko E
Temperature (Austin). 2016; 2(4):543-53.
PMID: 27227074
PMC: 4843929.
DOI: 10.1080/23328940.2015.1071700.
Donnelly W, Bartlett Jr D, Leiter J
Exp Physiol. 2016; 101(7):946-61.
PMID: 27121960
PMC: 5505555.
DOI: 10.1113/EP085716.
Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome.
Stasi C, Bellini M, Bassotti G, Blandizzi C, Milani S
Tech Coloproctol. 2014; 18(7):613-21.
PMID: 24425100
DOI: 10.1007/s10151-013-1106-8.
Activation of 5-HT3 receptors leads to altered responses 6 months after MDMA treatment.
Gyongyosi N, Balogh B, Katai Z, Molnar E, Laufer R, Tekes K
J Neural Transm (Vienna). 2010; 117(3):285-92.
PMID: 20052506
DOI: 10.1007/s00702-009-0357-z.
The 5-HT3 receptor--the relationship between structure and function.
Barnes N, Hales T, Lummis S, Peters J
Neuropharmacology. 2008; 56(1):273-84.
PMID: 18761359
PMC: 6485434.
DOI: 10.1016/j.neuropharm.2008.08.003.
Differential composition of 5-hydroxytryptamine3 receptors synthesized in the rat CNS and peripheral nervous system.
Morales M, Wang S
J Neurosci. 2002; 22(15):6732-41.
PMID: 12151552
PMC: 6758137.
DOI: 20026612.
Distribution of [3H]GR65630 binding in human brain postmortem.
Marazziti D, Betti L, Giannaccini G, Rossi A, Masala I, Baroni S
Neurochem Res. 2001; 26(3):187-90.
PMID: 11495540
DOI: 10.1023/a:1010939530412.
Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.
Plosker G, Milne R
Pharmacoeconomics. 1992; 2(4):285-304.
PMID: 10147044
DOI: 10.2165/00019053-199202040-00005.
Dorsal medullary 5-HT3 receptors and sympathetic premotor neurones in the rat.
Sevoz-Couche C, Nosjean A, Franc B, Hamon M, Laguzzi R
J Physiol. 1998; 508 ( Pt 3):747-62.
PMID: 9518730
PMC: 2230913.
DOI: 10.1111/j.1469-7793.1998.747bp.x.
The 5-HT3 receptor is present in different subpopulations of GABAergic neurons in the rat telencephalon.
Morales M, Bloom F
J Neurosci. 1997; 17(9):3157-67.
PMID: 9096150
PMC: 6573651.
Serotonin 5-HT3 receptor binding kinetics in the cortex of suicide victims are normal.
Mann J, Arango V, Henteleff R, Lagattuta T, Wong D
J Neural Transm (Vienna). 1996; 103(1-2):165-71.
PMID: 9026370
DOI: 10.1007/BF01292625.
Mediation by 5-HT3 receptors of an excitatory effect of 5-HT on dorsal vagal preganglionic neurones in anaesthetized rats: an ionophoretic study.
Wang Y, Ramage A, Jordan D
Br J Pharmacol. 1996; 118(7):1697-704.
PMID: 8842434
PMC: 1909830.
DOI: 10.1111/j.1476-5381.1996.tb15594.x.
Interaction of the antiemetic metopimazine and anticancer agents with brain dopamine D2, 5-hydroxytryptamine3, histamine H1, muscarine cholinergic and alpha 1-adrenergic receptors.
Herrstedt J, Hyttel J, Pedersen J
Cancer Chemother Pharmacol. 1993; 33(1):53-6.
PMID: 8269589
DOI: 10.1007/BF00686023.
Ondansetron, an antagonist of 5-HT3 receptors, antagonizes the anti-exploratory effect of caerulein, an agonist of CCK receptors, in the elevated plus-maze.
Vasar E, Peuranen E, Oopik T, Harro J, Mannisto P
Psychopharmacology (Berl). 1993; 110(1-2):213-8.
PMID: 7870888
DOI: 10.1007/BF02246976.
Interactions between 5-HT3 receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse.
Hagan R, Kilpatrick G, Tyers M
Psychopharmacology (Berl). 1993; 112(1 Suppl):S68-75.
PMID: 7831443
DOI: 10.1007/BF02245009.
An electrophysiological investigation of the properties of 5-HT3 receptors of rabbit nodose ganglion neurones in culture.
Peters J, Malone H, Lambert J
Br J Pharmacol. 1993; 110(2):665-76.
PMID: 7694755
PMC: 2175932.
DOI: 10.1111/j.1476-5381.1993.tb13863.x.
Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy.
Yarker Y, McTavish D
Drugs. 1994; 48(5):761-93.
PMID: 7530631
DOI: 10.2165/00003495-199448050-00008.
